Obesity is an important risk factor for the development of type 2 diabetes. The increasing incidence of obesity accounts in large part for the emergence of type 2 diabetes. Drug treatment of hyperglycaemia and hypertension lowers the risk of diabetic complications, but many of these treatments, including sulphonylureas, insulin and beta-blockers, are associated with weight gain. There is increasing evidence that obesity may be an independent risk factor for complications in both type 2 and type 1 diabetes. Therapies to lower body weight will undoubtedly have a role in the treatment of diabetes to potentially avert weight gain associated with anti-diabetic therapies, to lower glycaemia, and possibly even to lower the risk of diabetic complications. However, many questions remain to be answered.
Introduction
Obesity increases the risk of diabetes to a much greater extent than it increases the risk of other diseases. A US epidemiological study involving over 100,000 individuals found that, compared with people with body mass indices (BMI) < 22 kg=m 2 , individuals with BMI > 35 had a 30 -40-fold increased risk of diabetes, and a 2 -4-fold increased risk of other conditions 1 ( Figure 1 ). The prevalence of being overweight in type 2 diabetes is over 90%, compared with a much lower prevalence in the general population. Obesity as a risk factor for diabetes is independent of age, race and physical activity. While epidemiologists generally hesitate to attribute causality, the link between obesity and diabetes is very likely causal, and as such it is also likely that preventing obesity would prevent a large number of diabetes cases.
Effect of weight loss on risk of diabetes
Since being overweight and relatively inactive increases the risk of diabetes, it is logical to assume that reducing weight and increasing physical activity would decrease the risk of developing diabetes. In the past year, two studies have been published proving this to be the case. 2, 3 In addition to these studies, which are discussed in a further paper in this symposium, a Swedish cohort study provides impressive results relating treatment to enhance weight loss with lower a incidence of diabetes. The Swedish Obese Subjects study included a cohort of highly matched, severely obese subjects, of whom half had gastric surgery for obesity. After 8 y of follow-up, weight loss in the surgery group was approximately 20 kg compared with a non-significant increase of 0.5 kg in the control group. Gastric surgery was associated with a marked reduction in the incidence of diabetes (odds ratio 0.16), equivalent to a risk reduction of 84%. 4 Not only is the prevalence of type 2 diabetes increasing, the average age range at which it is being diagnosed is decreasing. US data show that between 1990 and 1998, the overall prevalence of diabetes in individuals aged 18 and over increased from 4.9 to 6.5%, an increase of 33%. The percentage increase was greatest among subjects aged 30 -39, a group in whom in the past type 2 diabetes was rarely seen 5 ( Table 1) . Type 2 diabetes is now diagnosed in adolescents and children; in the US, statistics suggest that 20% of diabetes in children is type 2 and cases have been recently reported in children in the UK. One of the reasons for this is that the prevalence of individuals considered overweight is increasing in children and teenagers. England is on course to match US levels of obesity, with half of women and two-thirds of men now considered to be overweight. 6 
Diabetic complications
The burden of diabetes relates not so much to its associated metabolic derangements, but rather to the complications associated with the disease. These include, among others, retinopathy, nephropathy, neuropathy and, most commonly, cardiovascular complications. Two of the most important risk factors for diabetic complications are hyperglycaemia and elevated systolic blood pressure. Unpublished data from the UK Prospective Diabetes Study (UKPDS) show that patients with type 2 diabetes together with raised systolic blood pressure and poor glycaemic control (high HbA 1c ) had a much greater risk of developing any diabetic complication over the 20 y of follow-up than individuals with either poor glycaemic control or high blood pressure, and a very much greater risk than individuals who had low blood pressure and good glycaemic control. The risk is continuous and extends into ranges of blood pressure and HbA 1c that would generally be considered normal.
The UKPDS showed that the treatment of blood glucose and blood pressure can reduce the risk of diabetic complications. 7, 8 An intensive glucose control policy compared with a less intensive policy (HbA 1c 7.0 vs 7.9%) was associated with a reduction in the risk of: diabetes-related endpoints by 12% (P ¼ 0.030); microvascular endpoints by 25% (P ¼ 0.010); myocardial infarction by 16% (P ¼ 0.052).
Showing a borderline significant reduction in risk of macrovascular end points. 7 Similarly, a policy of tight vs less tight blood pressure control (144=82 vs 154=87 mmHg) using either captopril or atenolol was associated with a risk reduction of:
any diabetes-related endpoint by 24% (P ¼ 0.005) any microvascular endpoint by 37% (P ¼ 0.009) stroke by 44% (P ¼ 0.013).
Weight gain with diabetes treatments
While treatment reduces the risk of diabetic complications, it can be associated with side effects. Hypoglycaemia can occur, but tends to be transient and weight gain is an important side effect. Patients in the UKPDS randomised to intensive control with sulphonylureas or insulin gained significantly more weight than patients who were initially randomized to diet ( Figure 2 ). 7 Weight gain can also be associated with treatment to reduce blood pressure particularly the beta-blockers; for example, patients taking atenolol in UKPDS had a mean weight gain of 3.4 kg over 9 y while those taking captopril gained 1.6 kg (P ¼ 0.02). 9 In patients in UKPDS who were over 120% normal body weight and were treated with metformin, there was minimal weight gain. 10 Metformin was, however, associated with a significant risk reduction of 39% for myocardial infarction, the most common complication of diabetes (Figure 3) . The mechanism by which this was achieved is not clear; treatment with metformin reduced HbA 1c by 0.6% (8 -7.4%), a Obesity and target organ damage A Adler magnitude of change that would be expected to result in only a 5 -10% risk reduction for myocardial infarction. This has led to the suggestion that metformin has actions in addition to its effect on blood glucose, and possibly associated with its lack of effect on body weight.
Effect of weight loss in type 2 diabetes
It is not known whether therapy to reduce weight in patients with diabetes prolongs life or reduces the risk of complications. However, it is known that reducing weight in patients with diabetes improves metabolic control. For example, in UKPDS, all patients following diagnosis of diabetes had 3 months' diet therapy before randomization to the study. In both men and women, diet led to reductions in BMI, body weight (nearly 4 -5 kg), HbA 1c (2%), fasting plasma glucose, plasma insulin and lipid values. 11 Although patients were not randomized to diet, these observational data on the effects of diet are nonetheless impressive (Table 2) .
Studies have shown, however, that patients with type 2 diabetes often find it more difficult to lose weight than nondiabetic obese individuals. 12 This may be because patients with type 2 diabetes are often older and have comorbidities that affect their body weight (thus requiring treatment with weight-loss-promoting agents, as mentioned above). Such patients may also have made previous attempts to lose weight, thereby reducing their success in further attempts. 13 One clinically important question is whether it is worthwhile treating obesity in patients with type 2 diabetes who have good blood pressure and glucose control. An important related question is, is obesity an independent risk factor for complications in type 2 diabetes? The answer is not entirely clear. At present, the evidence is strongest for renal complications. In UKPDS, the risk of microalbuminuria increased with increased blood pressure, increased HbA 1c , increased triglycerides, non-white ethnicity and increased white blood cell count, a possible marker for inflammatory factors. In addition, each 0.1 unit increase in waist -hip ratio was associated with a further 15% increase in risk. Obesity is, therefore, an independent risk factor for microalbuminuria.
An increased risk of microalbuminuria in overweight patients has also been observed in type 1 diabetes. 15 Patients with microalbuminuria are at risk of increasing renal dysfunction and also at increased risk of death from cardiovascular disease. Whether treatment of obesity will reduce the development and progression of nephropathy remains to be seen.
Type 1 diabetes
Obesity is not a risk factor for type 1 diabetes. Historically, type 1 diabetes patients were cachectic. However, as the population gets fatter, so too do people with type 1 diabetes and it is possible that obesity in a patient with type 1 diabetes is a risk factor for further complications. There is an emerging body of evidence suggesting that patients with type 1 diabetes and central adiposity have greater levels of surrogate markers for atherosclerosis. In the EURODIAB epidemiological study, 16 which involved over 3000 patients with type 1 diabetes, obesity was shown to be associated with a worsening of cardiovascular risk factors. Increase in the waist -hip ratio was associated with elevated cholesterol, lower HDL, elevated LDL and elevated triglycerides. It is likely that this elevation in risk factors would lead to a greater incidence of complications.
Unanswered questions
There is still much to learn on the subject of obesity and diabetes. Unanswered questions include:
Will treatments for obesity, including diet, drugs and physical exercise, lower the risk of cardiovascular complications in diabetes? Will treatments for obesity be beneficial in patients with good glycaemic and good blood pressure control, i.e. do we need to treat obesity above and beyond what we now consider to be standard treatment for diabetes? Should treatments for obesity accompany the start of hypoglycaemic therapies that are associated with weight Figure 3 Effect of different treatments of hyperglycaemia on risk of myocardial infarction in UKPDS.
Obesity and target organ damage A Adler gain as a way of moderating this side effect? With the growing prevalence of obesity, will patients with type 1 diabetes require treatment for obesity?
Summary
Obesity is an important risk factor for the development of type 2 diabetes. Hyperglycaemia and hypertension are strongly associated with diabetic complications and treatment with hypoglycaemic and antihypertensive drugs lowers the risk of complications. However, these treatments are often associated with weight gain. Obesity appears to be an independent risk factor for some complications in both type 2 and type 1 diabetes. Therapies to lower body weight, including diet and exercise, will undoubtedly have a role in the treatment of diabetes, although many questions remain to be answered.
